SIAMS-ONIG Consensus on hormonal treatment in gender identity disorders

Journal of Endocrinological Investigation

Volumn 32, Issue 10, 2009, Pages 857-864

  Godano, A ^a   Maggi, M ^b   Jannini, E ^c   Meriggiola, M C ^d   Ghigo, E ^e   Todarello, O ^f   Lenzi, A ^g   Manieri, C ^e  

^a Department of Plastic Surgery   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

^c UNIVERSITY OF L'AQUILA   (Italy)

^d UNIVERSITY OF BOLOGNA   (Italy)

^e UNIVERSITY OF TURIN   (Italy)

^f UNIVERSITY OF BARI   (Italy)

^g SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Cross sex treatment; Gender identity disorders (GID); Real life experience (RLE); Sex reassignment

Indexed keywords

ANTIANDROGEN; AZASTEROID; CYPROTERONE ACETATE; DUTASTERIDE; ESTRADIOL; ESTRADIOL VALERATE; ESTROGEN; FINASTERIDE; FLUTAMIDE; GESTAGEN; GONADORELIN DERIVATIVE; SPIRONOLACTONE; TESTOSTERONE; TESTOSTERONE ENANTATE; TESTOSTERONE UNDECANOATE;

ACNE; ALOPECIA; BREAST CANCER; CONFERENCE PAPER; CONSENSUS DEVELOPMENT; DEPRESSION; DRUG PREFERENCE; DRUG WITHDRAWAL; ECHOGRAPHY; ELECTROCARDIOGRAPHY MONITORING; ESTROGEN ACTIVITY; ESTROGEN THERAPY; FEMININITY; GENDER DYSPHORIA; GENDER IDENTITY DISORDER; HEALTH CARE POLICY; HEMATOLOGICAL PROCEDURES; HORMONAL THERAPY; HORMONE BLOOD LEVEL; HORMONE DETERMINATION; HORMONE SUBSTITUTION; HUMAN; LEGAL ASPECT; LIPID BLOOD LEVEL; LIVER TOXICITY; MASCULINITY; PATIENT MONITORING; PATIENT SELECTION; PRESCRIPTION; PSYCHOLOGIC ASSESSMENT; SEBORRHEA; SEX TRANSFORMATION; SIDE EFFECT; TREATMENT CONTRAINDICATION; TREATMENT DURATION; TREATMENT INDICATION; URINALYSIS; WEIGHT GAIN;

EID: 77349112195     PISSN: 03914097     EISSN: 17208386     Source Type: Journal    
DOI: 10.1007/BF03345758     Document Type: Conference Paper

References (22)

1. Osservatorio Nazionale sull'Identità di Genere - ONIG. Italian Standards of Care for Sex Reassignment in Gender Identity Disorder. www.onig.it
2. th ed, Text Revision). Washington DC: American Psychiatric Association, 2000.
3. Zitzmann M. The role of the CAG repeat androgen receptor polymorphism in andrology. Front Horm Res 2009, 37: 52-61.
4. Zitzmann M, Depenbusch M, Gromoll J, Nieschlag E. X-chromosome inactivation patterns and androgen receptor functionality influence phenotype and social characteristics as well as pharmacogenetics of testosterone therapy in Klinefelter patients. J Clin Endocrinol Metab 2004, 89: 6208-17.
5. Dahl M, Feldman JL, Goldberg JM, Jaberi A. Physical aspects of transgender endocrine therapy. Int J Transgenderism 2006, 9: 111-34.
6. Asscheman H, Gooren LJ, Assies J, Smits JP, de Slegte R. Prolactin levels and pituitary enlargement in hormone-treated male-to-female transsexuals. Clin Endocrinol (Oxf) 1988, 28: 583-8.
7. Istituto Superiore di Sanità. Conferenza Nazionale di Consenso. Salute della donna. Prevenzione delle complicanze trombotiche associate all'uso di estro-progestinici in età riproduttiva. Roma, 18-19 settembre 2008.
8. Benjamin H. Il fenomeno transessuale. Rome: Astrolabio Ubaldini Editore, 1966.
9. Futterweit W. Endocrine therapy of transsexualism and potential complications of long-term treatment. Arch Sex Behav 1998, 27: 209-26.
10. Godano A. Terapia medica nel transessualismo. G Ital Androl 1995, 2: 160-4.
11. Levy A, Crown A, Reid R. Endocrine intervention for transsexuals. Clin Endocrinol (Oxf) 2003, 59 : 409-18.
12. Jannini EA, Lenzi A, Wagner G. Behavioural therapy and counselling. In: Schill WB, Comhaire FH, Hargreave TB eds. Andrology for the Clinician. Berlin: Springer. 2006. 598-607.
13. Gooren LJ, Delemarre Van de Waal A. Hormone Treatment of Adult and Juvenile Transsexual Patients. In: Ettner R, Monstrey S, Eyler E eds. Principles of transgender medicine and surgery. The New York: Haworth Press, 2007.
14. Gooren LJ, Giltay EJ, Bunck MC. Long-term treatment of transsexuals with cross-sex hormones: extensive personal experience. J Clin Endocrinol Metab 2008, 93: 19-25.
15. Manieri C, Godano A, Lanfranco F, Di Bisceglie C, Ghigo E, Maggi M, Lenzi A, Jannini EA. Hormone treatment in gender dysphoria. Sexologies 2008, 17: 265-70.
16. Hembree WC, Cohen-Kettenis P, Delemarre-van de Waal HA, et al; Endocrine Society. Endocrine treatment of transsexuals persons: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2009, 94: 3132-54.
17. Cohen-Kettenis PT, Delemarre-van de Waal HA, Gooren U. The treatment of adolescent transsexuals: changing insight. J Sex Med 2008, 5: 1892-7.
18. Dittrich R, Binder H, Cupisti S, Hoffmann I, Beckmann MW, Mueller A. Endocrine treatment of male-to-female transsexuals using gonadotropin-releasing hormone agonist. Exp Clin Endocrinol Diab 2005, 113: 586-92.
19. Mueller A, Kiesewetter F, Binder H, Beckmann MW, Dittrich R. Long-term administration of testosterone undecanoate every 3 months for testosterone supplementation in female-to-male transsexuals. J Clin Endocrinol Metab 2007, 92: 3470-5.
20. Jacobeit JW, Gooren LJ, Schulte HM. Long-acting intramuscular testosterone undecanoate for treatment of female-to-male transgender individuals. J Sex Med 2007, 4: 1479-84.
21. Moore E, Wisniewski A, Dobs A. Endocrine treatment of transsexuals people: a review of treatment regimens, outcomes and adverse effects. J Clin Endocrinol Metab 2003, 88: 3467-73.
22. Mueller A, Gooren L. Hormone-related tumors in transsexuals receiving treatment with cross-sex hormones. Eur J Endocrinol 2008, 159: 197-202.